AstraZeneca selects Shanghai as its fifth global strategic hub, integrating R&D, commercial, and production operations.

AstraZeneca, a UK pharma giant, has named Shanghai as its fifth global strategic hub, integrating R&D, commercial, and production operations. The company sees significant opportunities to globalize local innovations and promote global recognition of Chinese clinical research data in Shanghai and the Yangtze River Delta region. AstraZeneca, present in China for over 30 years, is dedicated to exploring the vast Chinese market.

February 27, 2024
5 Articles